Audit: QRS - Norwegian 4x4 for Health & Longevity

Audit conducted on 09/08/2026 19:16 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	91
Passed	81
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Protocol, time-to-effect, benefit, risk, contraindication, interaction, monitoring and qualitative content all trace to ER Therapeutic Protocol, Practical Considerations, Expected Benefits, Potential Risks & Side Effects, Key Interactions & Contraindications and Monitoring Protocol & Defining Success.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindication thresholds and time windows carried at ER strength.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	All gate items originate in ER Key Interactions & Contraindications.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT identifiers, expert names or brand names appear in the QRS.
1.6	The QRS does not introduce new attributions.	🟢

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢
2.4	The QRS avoids language that implies medical or clinical advice	🟢	Statements are declarative descriptions of the protocol and its markers, not instructions.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the document.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical drug-class and biomarker terms are retained only where the ER requires them as decision gates.
2.8	Information is presented in a concise and very compact manner	🟢
2.9	It DOES NOT address the reader directly	🟢
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	Optimal-range monitoring targets rather than conventional laboratory cut-offs, per the ER.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed headings present verbatim (lines 446, 492, 540, 574, 590, 615, 647, 651–653, 803).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	77 named variable spans present, covering header, at-a-glance, three action sets, three time sets, four benefit tiers, both gates, four risk tiers, twelve marker triplets, cadence and seven qualitative items.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Structural spans (website="evidence_review", website="audit", website="full_review") and the footer disclaimer are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section feeding the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Frequency”, “Best time of day” and all seven qualitative-assessment labels match the ER bold labels verbatim; the monitoring rows carry the ER table’s biomarker names verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji characters in the file; the ER’s ⚠️ Conflicted markers are correctly not carried across.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is reduced to bare key facts; the print stylesheet targets A4 with 12mm margins.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after the doctype.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, correctly, because it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: norwegian_4x4_2026-0809-1633_Opus_ER.md
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.7.02
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	qrs_creation_date: 2026-0809-1836
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	qrs_creator_ai_nickname: Opus
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	qrs_creator_ai_fullname: Opus 5
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Matches the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	“Norwegian 4x4 for Health & Longevity - Quick Reference Sheet” (line 22).
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	2026-0809-1836 → 08/09/2026 (line 421).
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	“Opus 5” (line 425).
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header carries only title and the template subline.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses the protocol structure, the established fitness gain, the narrowed advantage and the dominant failure mode from ER lines 583–585.
7.2	[at_a_glance] is no longer than 60 words	🟢	58 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	“peak oxygen-use capacity” and “the fitness measure most tightly linked to living longer” replace VO2max terminology; no acronyms present.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	ER lines 397–406.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All nine ER “avoid or defer” entries present.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Lines 577–585.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	ER trailing clauses (“— absolute contraindication until cleared”, “— defer until treated, because of pressure surges…”) are all stripped.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“within 90 days”, “NYHA Class IV”, “valve area below 1.0 cm²”, “above 180/110 mmHg”, “before age 50”, “stage 4–5, eGFR below 30 mL/min/1.73 m²” all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER contraindication bullets use worded thresholds only; no ranking notation inside parentheses.
8.7	If no [stop_items] are present the section is left empty	N/A	Nine [stop_items] are present.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	ER lines 371–395.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All thirteen ER interaction bullets present; no overlap with the contraindication gate.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Lines 593–605.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s “— caution, requires target adjustment”, “— potentiating”, “— competing” clauses and all mitigation prose are stripped.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Named example drugs retained for every class, including the antioxidant thresholds (vitamin C above 1,000 mg, vitamin E above 400 IU daily).
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER interaction bullets contain only plain comma-separated drug lists; no ranking notation.
9.7	If no [caution_items] are present the section is left empty	N/A	Thirteen [caution_items] are present.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	ER Therapeutic Protocol, lines 436–450.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Standard protocol, frequency, and session timing — the three executable parameters of the ER protocol.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	All three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	Interval structure, recovery, warm-up/cool-down, session total, 48-hour spacing and the single-session constraint all trace to ER lines 436, 438, 448, 450.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Maximal oxygen uptake, blood pressure and insulin sensitivity — the three effects named in ER line 498.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Maximal oxygen uptake (High tier) first, then blood pressure and insulin sensitivity in ER Medium-tier order.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	All three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	4–6 weeks / 8–12 weeks / after a single session, with ER-supported subtexts.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four present and populated.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each tier is a semicolon-separated list of the ER benefit headings only.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheticals or magnitudes carried across.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers contain items in the ER.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four present and populated.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each tier lists the ER risk headings only.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	Surveillance rates, dropout percentages and prevalence figures are all absent.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers contain items in the ER.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	ER Monitoring Protocol & Defining Success, lines 528–545.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All twelve ER biomarker table rows are reproduced with their optimal ranges and rationales.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Daily, weekly, 12-week and 3-month cadences plus the 72-hour pre-draw rule, per ER lines 528 and 530.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	ER lines 549–555.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All seven ER qualitative markers present with their bold labels verbatim.

Issues 09/08/2026 19:16

Pass rate 100.00%. No issues found.

Issues 09/08/2026 19:09

1. 11.4 — Blood-pressure time-to-effect sub is empty of content: [time_2_sub] (QRS line 517) states “Changes emerge over this window”, a restatement of [time_2_value] “8–12 weeks” that adds no information, while the ER’s substantive point about the effect being largest at the highest starting pressures (ER lines 203, 269) goes unused.

Fixes 09/08/2026 19:09

1. 11.4 — Blood-pressure time-to-effect sub: Replaced the tautological [time_2_sub] “Changes emerge over this window” with “Largest absolute reductions where starting systolic pressure is highest”, drawn from ER lines 203 and 269.

Issues 09/08/2026 19:02

1. 4.2 / 4.3 — Invented Protocol cell labels: [action_1_label] “Session” (line 450) and [action_3_label] “Timing & structure” (line 478) are invented; the corresponding ER Protocol bullets carry the bold labels “Standard protocol as used in the Trondheim research programme” (ER line 436) and “Best time of day” (ER line 448).

Fixes 09/08/2026 19:02

1. 4.2 / 4.3 — Protocol cell labels aligned to ER: [action_1_label] changed from “Session” to “Standard protocol” and [action_3_label] from “Timing & structure” to “Best time of day”, so both derive from the ER Protocol bullets’ own bold labels rather than invented wording.

Issues 09/08/2026 18:53

1. 8.5 — Severity qualifiers dropped from contraindications: Two severity classes were dropped rather than preserved — “severe left ventricular outflow tract obstruction” appears as “outflow tract obstruction” (line 577) and “untreated high-risk inherited arrhythmia syndromes” appears as “untreated inherited arrhythmia syndromes” (line 578), both of which broaden the gate beyond what the ER states.

Fixes 09/08/2026 18:53

1. 8.5 — Severity qualifiers restored in contraindications: Restored the two dropped severity classes in [stop_items] — “outflow tract obstruction” changed back to “severe left ventricular outflow tract obstruction”, and “untreated inherited arrhythmia syndromes” changed back to “untreated high-risk inherited arrhythmia syndromes”, matching the ER wording.

Issues 09/08/2026 18:48

1. 4.5 / 2.8 — Content exceeds one A4 page: The sheet carries roughly twice the printable A4 budget — the decision-gate column runs ~28 wrapped lines and the Monitoring table ~12 multi-line rows plus a four-line cadence note — because contraindications (lines 576–584), interactions (lines 592–604), Monitoring targets and rationales (lines 656–787) and the qualitative items (lines 805–847) reproduce near-verbatim ER prose instead of compacted facts.

Fixes 09/08/2026 18:48

1. 4.5 / 2.8 — Contraindications condensed: Trimmed redundant wording from the nine [stop_items] (e.g. “acute myocardial infarction within 90 days” → “myocardial infarction within 90 days”, “Uncontrolled hypertension with resting blood pressure above 180/110 mmHg” → “Uncontrolled hypertension above 180/110 mmHg”) while keeping every threshold, time window and staging qualifier.
2. 4.5 / 2.8 — Key Interactions condensed: Shortened the thirteen [caution_items] by replacing connective prose with commas and trimming example lists to their drug or substance names (e.g. “beetroot or dietary nitrate, potassium, magnesium, garlic extract, hibiscus” → “nitrate, potassium, magnesium, garlic, hibiscus”), with all named examples retained.
3. 4.5 / 2.8 — Monitoring rationales compacted: Rewrote eleven of the twelve “Why” cells and the VO2max “Target” cell as compact clauses instead of near-verbatim ER sentences (e.g. “Counts the atherogenic particles that drive cardiovascular events, the outcome the protocol is ultimately aimed at” → “Counts the atherogenic particles that drive cardiovascular events”).
4. 4.5 / 2.8 — Monitoring cadence shortened: Reduced [monitoring_cadence] from 310 to 253 characters by dropping filler (“an objective fitness reassessment at 12 weeks, then every 6 months” → “fitness reassessment at 12 weeks then every 6 months”).
5. 4.5 / 2.8 — Qualitative items shortened: Compacted six of the seven qualitative entries (e.g. “sustained aversion to starting indicates frequency or intensity should be reduced” → “sustained aversion indicates reducing frequency or intensity”).
6. 4.5 / 2.8 — Protocol and Time-to-Effect subtext trimmed: Removed duplicated detail from [action_1_sub], [action_3_sub], [time_1_sub] and [time_3_sub] (e.g. “Detectable after a single session, but ongoing session frequency is required for the effect to persist” → “Ongoing session frequency is required for the effect to persist”, the single-session detail already being carried by [time_3_value]).

Issues 09/08/2026 18:42

1. 1.1 — Insulin time-to-effect overstated and misattributed: time_3_sub says insulin-sensitivity change is “Detectable immediately” (ER line 498 says “after a single session”) and appends the ER’s general statement about subjective changes preceding measurable ones as if it applied to insulin sensitivity.
2. 2.5 — Imperative protocol instruction: action_3_value (line 481) reads “Finish at least 3 hours before bedtime”, an instruction to the reader rather than a presented fact; the ER states it as “a finish at least three hours before bedtime” (ER line 448).

Fixes 09/08/2026 18:42

1. 1.1 — Insulin time-to-effect wording corrected: time_3_sub changed from “Detectable immediately, but ongoing frequency is required to persist; subjective changes precede measurable ones by a week or two” to “Detectable after a single session, but ongoing session frequency is required for the effect to persist”, matching the ER and removing the misattributed subjective-changes clause.
2. 2.5 — Imperative protocol instruction removed: action_3_value changed from “Finish at least 3 hours before bedtime” to “Session ends at least 3 hours before bedtime”, so the cell states a fact rather than instructing the reader.